AI in Clinical Decisions: Verifying Utility Beyond the Hype

Generative AI promises huge efficiency and diagnostic gains in clinical decision support. But for venture capital partners and diligence officers in this fast-growing sector, telling the difference between real clinical utility and marketing fluff is everything. This brief gives you a framework for looking at clinical large language models (LLMs), focused on what matters: safety, performance, and regulation.

Working through the Hallucination Hazard in Clinical LLMs

The biggest problem with clinical generative AI is “hallucination”, when a model generates factually incorrect or nonsensical information. In a hospital, that kind of error can cause serious harm or death. A wrong answer from a consumer chatbot might be funny, but a clinical LLM that spits out a bogus diagnostic path or treatment plan is a non-starter. For investors, this means you have to scrutinize any peer-reviewed benchmarks on hallucination rates. A company’s safety claims must be backed by tough, independent testing published in real scientific journals, not just their own whitepapers. These studies need to spell out the methodology, the exact clinical scenarios they tested, and how they measured hallucinations. A model’s score on a standardized medical Q&A dataset that was graded by board-certified doctors, for example, has a lot more weight than some generic accuracy percentage. Hallucination rates in medical AI can be all over the place depending on the task. For instance, summarizing a medical case can produce hallucinations 64.1% of the time without specific prompts, though you can cut that down by about 33% with the right prompting. When it comes to clinical documentation, the per-sentence error rate might be as low as 1.47%, but 44% of those errors could be clinically significant. And don’t even get started on citations. GPT-3.5 was found to fabricate 55% of its references, while GPT-4 got it down to 18%, and some earlier LLMs had fabrication rates as high as 91.4%. A 2025 global survey found that 91.8% of clinicians reported seeing AI hallucinations, and 84.7% of them believed these errors could directly harm a patient. The National Academy of Medicine has been clear about the need for transparent reporting on AI performance metrics, especially around safety and bias, if we want to build trust and get these tools adopted responsibly National Academy of Medicine AI in health guidance. Companies like Hippocratic AI are now building safety-focused clinical language models from the ground up, which is a major shift. Instead of just tweaking a general-purpose LLM and hoping for the best, these purpose-built models with safety baked in are becoming the standard for clinical work. Your diligence process should dig deep into this “safety-first” engineering. What datasets did they use for training and fine-tuning? What error detection and correction systems are built into the model’s architecture?

The Regulatory Imperative: FDA Clearance and SaMD Considerations

For any clinical AI tool, getting regulatory clearance is a de-risking event that directly affects a company’s funding and its ability to even enter the market. The Food and Drug Administration’s (FDA) guidance on Software as a Medical Device (SaMD) is the key document here, especially for gen AI tools meant for clinical decision support. Most of these applications will be classified as SaMD, which means it’s software designed for a medical purpose that runs on its own, without being part of a physical medical device. This classification opens up specific regulatory paths, usually the 510(k) clearance process for devices that are “substantially equivalent” to something already on the market, or the De Novo path for new, low-to-moderate-risk devices with no existing equivalent. Investors have to verify the FDA clearance status for any generative model a startup plans to sell for clinical use. As a sign of what’s possible, UpDoc Inc. got FDA clearance on December 23, 2025, for the first SaMD that uses patient-facing LLMs for medication management, which they announced publicly on June 25, 2026. This shows a path exists. The FDA also updated its guidance on Clinical Decision Support Software on January 6, 2026, which further shapes the field. If a company has no clear regulatory strategy or isn’t already talking to the FDA, that’s a huge red flag. The FDA’s focus on a Predetermined Change Control Plan (PCCP) for AI/ML medical devices is also incredibly important. A PCCP lets a company make certain pre-approved changes to its algorithms without having to go through a whole new premarket submission every time, which is absolutely essential for models designed to learn and get better over time. Think about it: without a PCCP, every single model retrain or update could trigger a new 510(k) filing. That’s an unscalable regulatory nightmare that would crush your time to market and revenue plans. Diligence needs to confirm the company has a real strategy for handling algorithmic drift and model updates inside an FDA-approved plan. The FDA is still figuring this out, too. They issued a discussion paper on August 18, 2026, asking for feedback on how to regulate generative AI in medical devices FDA guidance on AI/ML medical device change control.

Beyond Infrastructure: Verifiable Clinical Utility from Google Cloud to End-User Applications

Foundational model providers like Google Cloud offer some very powerful LLM infrastructure for healthcare, but that doesn’t mean the applications built on top of it have any proven clinical value. The utility for the end-user, whether it’s a hospital system or a clinician at the bedside, has to be demonstrated at the application layer. Google Cloud’s tools give you the raw computing power and data plumbing needed for these complex AI models, but they don’t automatically make your application clinically safe or compliant. As a venture partner, you have to be able to separate the strength of the underlying platform from the actual, verified performance of the specific app you’re looking at. A startup using Google’s healthcare AI tools is still 100% responsible for its own model’s accuracy, safety, and regulatory approval. We see this “Innovation vs. Hype” dynamic all the time, where startups brag about their sophisticated tech stack but have zero evidence of clinical impact or that they’ve even thought about the regulatory side. You should be looking for applications that have gone through proper clinical accuracy trials, ideally randomized controlled trials (RCTs) or at least compelling real-world evidence (RWE) studies, showing they either improve patient outcomes or make clinical workflows more efficient without adding risk. The quality of this clinical evidence is a very strong predictor of a company’s commercial success and whether they’ll ever get a clear path to reimbursement.

A Framework for Diligence: Cutting Through the Noise

For diligence officers, looking at generative AI startups in the clinical space means you need a system to get past the marketing. Here’s a working framework:

• Hallucination Rate Benchmarks: Demand the peer-reviewed data on hallucination rates for relevant clinical tasks. These rates will vary wildly by model and what mitigation tactics are used. Ask: What’s the methodology? Who validated the results?
• FDA Clearance Status: Verify their current or planned FDA pathway (510(k), De Novo, Breakthrough). You need to understand their regulatory strategy and timeline, keeping in mind that the first patient-facing LLM SaMD just got clearance in late 2025.
• PCCP Implementation: Does the company have a clear Predetermined Change Control Plan, or are they at least actively working on one with the FDA for their model updates?
• Clinical Evidence: Look for published clinical outcomes and, even better, signed payer contracts. Companies that have strong clinical validation and solid RWE are the ones that will secure more durable funding. Example of a peer-reviewed clinical accuracy study for an LLM.
• Data Moat & GMLP: Evaluate the proprietary datasets that give the company its competitive edge (its “data moat”). You also need to ask about their adherence to Good Machine Learning Practice (GMLP) principles, which are the guidelines for developing safe and effective AI/ML medical devices.
• QMS and Security: Make sure a real Quality Management System (QMS) is in place (like ISO 13485). Data security and privacy compliance (HIPAA, HITRUST, SOC 2) must be baked in from the beginning, not tacked on as an afterthought.

Methodology and Source Note

This analysis is based on a review of published clinical accuracy trials for large language models, current FDA digital health guidance, and the day-to-day realities of healthcare AI venture capital. We’re prioritizing factual data and verified regulatory filings, not speculative claims. Our goal is to give clinical-tech venture partners and diligence officers a data-driven way to make informed investment decisions in this field. The players we’ve mentioned, like Google Cloud, Hippocratic AI, and the FDA, are all central to how generative AI in healthcare will unfold. This content is from the AI Health Investment Tracker, which delivers authoritative, data-driven insights.